Biotech Stocks Featured Investing Stock Market Today Stocks to Watch

3 Biotech Stocks To Watch Before December 2023

Biotech stocks to check out in the stock market today.

The biotechnology sector is a dynamic and innovative field that combines biological sciences with technology. It encompasses a range of companies focusing on medical research, pharmaceuticals, and genetic engineering. These companies work on groundbreaking treatments, vaccines, and technologies. The sector is known for its potential to significantly impact healthcare and agriculture.

Investing in biotech stocks can be both exciting and challenging. These stocks are often associated with high volatility. This is due to the nature of the biotech industry, where a company’s success often hinges on clinical trial results and regulatory approvals. Investors in biotech stocks must be prepared for sudden market movements. This is often driven by news of drug approvals or setbacks.

When considering biotech stocks, thorough research is key. It’s important to understand the company’s pipeline of products, the stages of clinical trials, and the market potential of its innovations. Investing in biotech requires patience and a higher tolerance for risk. However, successful investments in this sector can offer substantial rewards. This is due to the vital nature of biotech products and their impact on health and well-being. That said, here are three biotech stocks to watch in the stock market right now.

Biotech Stocks To Buy [Or Avoid] Now

Regeneron Pharmaceuticals (REGN Stock)

First up, Regeneron Pharmaceuticals Inc. (REGN) is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron’s notable products include treatments for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases.

Earlier this month, Regeneron Pharmaceuticals reported a beat for its third quarter 2023 financial results. In detail, the company posted Q3 2023 earnings of $11.64 per share, on revenue of $3.36 billion. This is compared to estimates for the quarter which were an EPS of $10.86 per share with revenue of $3.22 billion. Moreover, revenue increased by 14.53% versus the same period, the prior year.

Looking at the last month of trading action, shares of REGN stock have advanced by 3.07%. While, during Monday morning’s trading session, Regeneron Pharmaceuticals stock opened slightly higher by 0.089%, trading at $799.01 per share.

[Read More] 3 High Dividend Stocks For Your November 2023 Watchlist

Vertex Pharmaceuticals (VRTX Stock)

Next, Vertex Pharmaceuticals Incorporated (VRTX) specializes in developing and commercializing therapies for treating cystic fibrosis (CF) and other serious diseases. Recognized for its CF treatments, Vertex is expanding its research to address other life-threatening diseases, including pain, cancer, inflammatory diseases, and neurological disorders.

Just this month, Vertex Pharmaceuticals announced better-than-expected third-quarter 2023 financial results. Specifically, the biotech company reported Q3 2023 earnings of $4.12 per share, along with revenue of $2.48 billion. This is versus Wall Street’s estimates for the quarter which were earnings of $3.98 per share, with revenue of $2.50 billion. Meanwhile, revenue for the quarter grew by 6.39% compared to the same period, the previous year.

In the last month of trading, shares of VRTX stock have pulled back by 1.08%. Continuing on, during Monday morning’s trading session, Vertex Pharmaceuticals opened modestly lower off the open by 0.45% at $351.44 per share.

[Read More] Top AI Stocks To Buy Right Now? 3 To Know

Johnson & Johnson (JNJ Stock)

Lastly, Johnson & Johnson (JNJ) is a global healthcare conglomerate that focuses on the research and development, manufacture, and sale of a broad range of products in the healthcare field. It operates through three main segments: Pharmaceutical, Medical Devices, and Consumer Health, offering a wide array of products from prescription drugs and medical devices to personal care and over-the-counter products.

Last month, Johnson & Johnson also announced its Q3 2023 earnings results. Getting right into it, the healthcare giant reported a beat notching in earnings of $2.66 per share, with revenue of $21.35 billion. This was compared to analysts’ estimates for the quarter which were an EPS of $2.52 and revenue estimates of $21.04 billion.

In the last month of trading, Johnson & Johnson stock increased by 4.11%. Meanwhile, on Monday morning, JNJ stock is trading lower on the day so far by 0.61% at $151.58 a share.

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

By Jonathan Phillip

Jonathan Phillip is an up and coming financial contributor in the stock market today. He's found a strong niche in writing about true growth industries. His main focus for the last 5 years has been on the cannabis industry and marijuana stocks. He is one of the top contributors to cannabis media outlets like He also is head of social media management for

Since an early age, Jonathan has been an active member of the cannabis culture. Coming from Miami, Florida, he's been able to identify emerging trends in the space including the emergence of cannabis derivatives, vapes, e-liquids, wax, and more. His ability to identify emerging niches has afforded him the ability to source valuable information from top industry names.

Jonathan has also managed to build a strong social media presence for companies. He has worked with hundreds of public companies to develop a digital presence. As an active blogger and social media influencer, his focus is on lifestyle segments of the market. You can find Jonathan reporting on anything from industry conferences and investor events to corporate disclosures and cannabis market movers.

Since the early days of marijuana companies going public, Jonathan has made it a point to find information before the crowd. The main target of his writing is on undiscovered or under-researched companies that could hold true, lasting market potential. Through his research, Jonathan has managed to be one of the early writers to identify the opportunity of cannabis over other things like alcohol and he was one of the first reporters to cover the multi-billion dollar deals that materialized in 2017 and 2018. He has also covered the emergence of multi-state operators in the U.S. after Canada paved the way in late 2018 and 2019 for legalization in North America.

Jonathan is also an active member of the underground hip-hop scene. He has worked with some of the biggest names in the rap community while also gaining valuable insight from top producers and business moguls focused on moving brands forward. In his free time, Jonathan builds social communities and continues to hone his skills as a leading financial writer.

Notify of
Inline Feedbacks
View all comments